Citation:
Xue Zheng, Jizhen Xie, Xing Zhang, Weiting Sun, Heyang Zhao, Yantuan Li, Cheng Wang. Corrigendum to "An overview of polymeric nanomicelles in clinical trials and on the market" [Chinese Chemical Letters 32 (2021) 243-257][J]. Chinese Chemical Letters,
2025, 36(2): 110545.
doi:
10.1016/j.cclet.2024.110545
Corrigendum to "An overview of polymeric nanomicelles in clinical trials and on the market" [Chinese Chemical Letters 32 (2021) 243-257]
English
Corrigendum to "An overview of polymeric nanomicelles in clinical trials and on the market" [Chinese Chemical Letters 32 (2021) 243-257]
-
The authors regret <According to ref. [90], the sentence on page 249 "A Phase Ⅰ/Ⅱ trial of NC-6004 plus gemcitabine for metastatic pancreatic cancer was conducted in Taiwan and Singapore (n = 22) [90]." should be revised to "A Phase Ⅰ/Ⅱ trial of NC-6004 plus gemcitabine for metastatic pancreatic cancer was conducted in the United States and Europe (n = 22) [90].">.
The authors would like to apologise for any inconvenience caused.
-
扫一扫看文章
计量
- PDF下载量: 0
- 文章访问数: 8
- HTML全文浏览量: 1
下载:
